PIK3C2A and Thrombocytopenia: Furthermore, COMBO treatment did not seem to increase the risk of adverse events, including AKI, CPK elevation, and thrombocytopenia, but there was a trend toward increased CDI risk with COMBO, this potential safety signal warrants particular consideration.